| Literature DB >> 27855717 |
Isaac Ssinabulya1, Yvonne Nabunnya2, Brian Kiggundu2, Charles Musoke3, Michael Mungoma3, James Kayima2.
Abstract
BACKGROUND: Hypertension is as prevalent in many developing countries, as in the developed world and is the leading cause of cardiovascular morbidity and mortality in Africa. The control of hypertension in this resource limited setting is inadequate, a situation that translates into poorer outcomes in form of increasing incidences of stroke, heart failure, kidney failure and therefore early cardiovascular death.Entities:
Keywords: Blood pressure control; Hypertension; Management; Tertiary clinic
Mesh:
Substances:
Year: 2016 PMID: 27855717 PMCID: PMC5114775 DOI: 10.1186/s13104-016-2293-y
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Factors associated with blood pressure control
| Variable | Controlled blood pressure | Uncontrolled blood pressure | Odds ratio | p value | Adjusted odds ratio | p value |
|---|---|---|---|---|---|---|
| Age | 61 (51–71) | 59 (50–70) | 1.01 (1.00–1.02) | 0.195 | ||
| Gender—female | 182 (91.9) | 460 (84.7) | 2.05 (1.17–3.60) | 0.012 | 1.85 (1.03–3.34) | 0.04 |
| ARBs | 78 (39.4) | 232 (42.7) | 0.87 (0.63–1.21) | 0.416 | ||
| ACEi | 55 (27.8) | 201 (37.0) | 0.65 (0.46–0.93) | 0.02 | 0.53 (0.36–0.78) | 0.001 |
| Beta blockers | 94 (47.5) | 293 (54.0) | 0.77 (0.56–0.83) | 0.118 | 0.62 (0.44–0.88) | 0.008 |
| Calcium channel blockers | 127 (64.1) | 409 (75.3) | 0.58 (0.41–0.83) | 0.003 | 0.54 (0.37–0.78) | 0.002 |
| Centrally acting | 5 (2.53) | 31 (5.71) | 0.43 (0.16–1.12) | 0.083 | 0.36 (0.13–0.98) | 0.046 |
| Thiazide diuretic | 120 (60.6) | 388 (71.5) | 0.61 (0.44–0.86) | 0.005 | 0.54 (0.38–0.78) | 0.001 |
| Potassium sparing | 9 (4.55) | 15 (2.76) | 1.67 (0.72–3.89) | 0.23 | ||
| Number of anti-hypertensive drugs | ||||||
| One | 20 (10.1) | 22 (4.1) | [ | |||
| Two | 82 (41.4) | 154 (28.4) | 0.59 (0.30–1.14) | 0.113 | ||
| Three | 69 (34.9) | 239 (44.0) | 0.32 (0.16–0.62) | 0.001 | ||
| Four | 18 (9.1) | 116 (21.4) | 0.17 (0.08–0.37) | <0.001 | ||
| Five | 5 (2.5) | 9 (1.7) | 0.61 (0.18–2.13) | 0.44 | ||
| Having all investigations | 24 (12.1) | 79 (14.5) | 0.81 (0.50–1.32) | 0.399 | ||
| Having any comorbidity | 25 (12.6) | 65 (12.0) | 1.06 (0.65–1.74) | 0.809 | ||
| Keeping appointment | 94 (48.2) | 252 (47.5) | 1.03 (0.74–1.43) | 0.858 | ||
ARBs angiotensin receptor blockers, ACEi angiotensin converting enzyme inhibitor
Patient characteristics
| Variable | Female n (%) | Male n (%) | Total n (%) |
|---|---|---|---|
| Age categories (years) | |||
| <40 | 36 (5.8) | 5 (5.2) | 41 (5.7) |
| 40–49 | 111 (17.9) | 15 (15.6) | 126 (17.6) |
| 50–59 | 172 (27.8) | 20 (20.8) | 192 (26.9) |
| 60–69 | 141 (22.8) | 18 (18.7) | 159 (22.2) |
| 70–79 | 121 (19.6) | 25 (26.0) | 146 (20.4) |
| 80 and above | 38 (6.1) | 13 (13.5) | 51 (7.1) |
| Biophysical measurements done | |||
| Weight | 234 (36.5) | 30 (30.3) | 264 (35.6) |
| Height | 148 (22.7) | 20 (20.2) | 168 (22.7) |
| WHR | 2 (0.3) | 0 | 2 (0.3) |
| Investigations done | |||
| Complete blood count | 231 (36.0) | 35 (35.4) | 266 (35.9) |
| Urinalysis | 209 (32.6) | 34 (34.3) | 243 (32.8) |
| Renal function tests | 292 (45.5) | 47 (47.5) | 339 (45.8) |
| Chest X-ray | 114 (17.8) | 18 (18.2) | 132 (17.8) |
| Echo | 284 (44.2) | 48 (48.5) | 332 (44.8) |
| ECG | 290 (45.2) | 51 (51.5) | 341 (46.0) |
| Medication | |||
| ACEi or ARB | 464 (72.27) | 75 (75.76) | 539 (72.74) |
| Beta blocker | 345 (53.7) | 42 (42.4) | 387 (52.2) |
| Calcium channel blocker | 454 (70.7) | 82 (82.8) | 536 (72.3) |
| Thiazide diuretic | 438 (68.2) | 70 (70.7) | 508 (68.6) |
| Centrally acting vasodilator | 29 (4.5) | 7 (7.1) | 36 (4.9) |
| Potassium sparing | 21 (3.3) | 3 (3.0) | 24 (3.2) |
| Furosemide | 26 (4.1) | 13 (13.1) | 39 (5.3) |
| Co-morbidity | 23 (23.3) | 67 (10.4) | 90 (12.2) |
| Blood pressure control | 182 (28.4) | 16 (16.2) | 198 (26.7) |
| Missed appointment | 301 (47.9) | 45 (46.4) | 346 (47.7) |
ARBs Angiotensin receptor blockers, ACEi Angiotensin converting enzyme inhibitor
Type of drugs used
| n (%) | |
|---|---|
| One drug (5.8% n = 43) | |
| ARBs/ACEi | 10 (23.3) |
| Calcium channel blocker | 10 (23.3) |
| Diuretics | 5 (11.6) |
| Beta blocker | 15 (34.9) |
| Centrally acting vasodilator | 1 (2.3) |
| Potassium sparing diuretic | 2 (4.6) |
| Two drugs (32.8% n = 243) | |
| ARBs/ACEi and beta blocker | 33 (13.6) |
| ARBs/ACEi and calcium channel blocker | 66 (27.2) |
| ARBs/ACEi and thiazide diuretic | 37 (15.2) |
| Beta blocker and calcium channel blocker | 16 (6.6) |
| Beta blocker and thiazide diuretic | 37 (15.2) |
| Others | 6 (2.5) |
| Three drugs (42.2% n = 313) | |
| ARBs/ACEi, beta blocker and calcium channel blocker | 53 (16.9) |
| ARBs/ACEi, beta blocker and thiazide diuretic | 42 (13.4) |
| ARBs/ACEi calcium channel blocker and thiazide diuretic | 149 (47.6) |
| Beta blocker, calcium channel blocker and thiazide diuretic | 55 (17.6) |
| Others | 14 (4.5) |
| Four drugs (16.5 n = 122) | |
| ARBs/ACEi, beta blocker, calcium channel blocker and thiazide diuretic | 102 (83.6) |
| ARBs/ACEi, calcium channel blocker thiazide diuretic and centrally acting vasodilator | 6 (4.9) |
| Others | 14 (11.5) |
| Five drugs (1.9% n = 14) | |
| ARBs/ACEi, beta blocker, calcium channel blocker, thiazide diuretic and centrally acting vasodilator | 5 (35.7) |
| ARBs/ACEi, beta blocker, calcium channel blocker, thiazide diuretic and potassium sparing diuretic | 8 (57.1) |
| ARBs/ACEi, beta blocker, calcium channel blocker, centrally acting vasodilator and potassium sparing diuretic | 1 (7.1) |
ARBs angiotensin receptor blockers, ACEi angiotensin converting enzyme inhibitor